Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Benchmark Maintains Buy on Plexus, Raises Price Target to $105

Benchmark analyst David Williams maintains Plexus (NASDAQ:PLXS) with a Buy and raises the price target from $101 to $105.

byBenzinga Newsdesk

August 29, 2022

1 minute read

Benchmark analyst David Williams maintains Plexus (NASDAQ:PLXS) with a Buy and raises the price target from $101 to $105.

Over $17 Million Bet On This Electric Vehicle Stock? 4 Stocks Insiders Are Buying

By Lisa Levin

Today, 2:46 AM

Although US stocks closed higher on Wednesday, there were a few notable insider trades.

HPK

Jefferies Upgrades Prestige Consumer to Buy, Raises Price Target to $70

By Benzinga Newsdesk

Today, 2:46 AM

Jefferies analyst Stephanie Wissink upgrades Prestige Consumer (NYSE:PBH) from Hold to Buy and raises the price target from $65 to $70.

PBH

Stoke Therapeutics Announces Interim Safety, PK And CSF Exposure Data From Phase 1/2a MONARCH Study Of STK-001

By Bill Haddad

Today, 2:46 AM

– Results show that single doses of STK-001 up to 30mg and multiple doses of 20mg were well-tolerated with no safety concerns related to the study drug – – A trend toward a reduction in convulsive

STOK

B of A Securities Upgrades Synopsys to Neutral, Raises Price Target to $360

By Benzinga Newsdesk

Today, 2:46 AM

B of A Securities analyst Vivek Arya upgrades Synopsys (NASDAQ:SNPS) from Underperform to Neutral and raises the price target from $325 to $360.

SNPS

Benchmark Maintains Buy on Plexus, Raises Price Target to $105

Related Posts

Over $17 Million Bet On This Electric Vehicle Stock? 4 Stocks Insiders Are Buying

Jefferies Upgrades Prestige Consumer to Buy, Raises Price Target to $70

Stoke Therapeutics Announces Interim Safety, PK And CSF Exposure Data From Phase 1/2a MONARCH Study Of STK-001

B of A Securities Upgrades Synopsys to Neutral, Raises Price Target to $360